SPA
CAPR icon

Sherbrooke Park Advisers’s Capricor Therapeutics CAPR Stock Holding History

Sherbrooke Park Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,472
Closed -$104K – 535
2025
Q2 		$104K Buy
+10,472
New +$111K 0.05% 458

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sherbrooke Park Advisers's CAPR Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 10,472 shares — an estimated $104K sold.

Sherbrooke Park Advisers first reported a position in CAPR in Q2 2025 and held it in 1 quarter. The position peaked at $104K in Q2 2025. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,472 Capricor Therapeutics shares in Q3 2025, an estimated $104K.
  • Sherbrooke Park Advisers first reported a position in Capricor Therapeutics in Q2 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Capricor Therapeutics position peaked at $104K in Q2 2025.
  • 115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.